| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Hydroxyzine 2HCl (NSC-169188; NSC169188; Arcanax; Neurolax; Orgatrax; Pamoate, Hydroxyzine; Vistaril), the dihydrochloride salt of hydroxyzine, is a potent histamine H1-receptor antagonist and an antihistamine drug used in the treatment of itchiness, anxiety, and nausea. It has an IC50 of 10 nM/19 nM and inhibits the binding of [3H]pyrilamine/[3H]desloratadine to the human histamine H1 receptor. Hydroxyzine does make you sleepy, in contrast to its primary metabolite cetirizine.
| Targets |
Histamine H1 receptor ( IC50 = 10 nM-19 nM )
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
|
| Molecular Formula |
C21H29CL3N2O2
|
|---|---|
| Molecular Weight |
447.83
|
| Exact Mass |
446.13
|
| Elemental Analysis |
C, 56.32; H, 6.53; Cl, 23.75; N, 6.26; O, 7.15
|
| CAS # |
2192-20-3
|
| Related CAS # |
Hydroxyzine-d4 dihydrochloride;1219805-91-0;Hydroxyzine pamoate;10246-75-0;Hydroxyzine;68-88-2;Hydroxyzine-d4 dihydrochloride;Hydroxyzine-d8 dihydrochloride;1808202-93-8
|
| Appearance |
Solid powder
|
| SMILES |
C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl
|
| InChi Key |
ANOMHKZSQFYSBR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H27ClN2O2.2ClH/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25;;/h1-9,21,25H,10-17H2;2*1H
|
| Chemical Name |
2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol;dihydrochloride
|
| Synonyms |
Hydroxyzine dihydrochloride; NSC 169188; U.C.B 4492; Hydroxyzine hydrochloride; NSC-169188; NSC169188; trade names: Arcanax; Neurolax; Orgatrax; Pamoate, Hydroxyzine; Vistaril
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (223.30 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
Solubility in Formulation 2: Saline: 30 mg/mL (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2330 mL | 11.1650 mL | 22.3299 mL | |
| 5 mM | 0.4466 mL | 2.2330 mL | 4.4660 mL | |
| 10 mM | 0.2233 mL | 1.1165 mL | 2.2330 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06080100 | Not yet recruiting | Drug: Xenon Other: premedication hydroxyzine 25 mg |
Anesthesia Anxiety |
The S.N. Fyodorov Eye Microsurgery State Institution |
November 1, 2023 | Early Phase 1 |
| NCT05680584 | Recruiting | Drug: Melatonin 3 MG Drug: Hydroxyzine Pill |
Effect of Drug Anxiety |
Minia University | February 1, 2023 | Phase 1 |
| NCT05737511 | Not yet recruiting | Drug: Hydroxyzine Drug: Escitalopram Oxalate |
Panic Disorder | Sultan Qaboos University | December 30, 2023 | Phase 4 |
| NCT04188106 | Completed | Drug: Varenicline Pill Drug: Hydroxyzine Pill |
Stress Nausea Smoking Cessation |
Rose Research Center, LLC | June 17, 2019 | Phase 4 |
| NCT00661674 | Completed | Drug: Palonosetron Drug: Hydroxyzine |
Substance-Related Disorders | Stanford University | April 2008 | Not Applicable |
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
